Business
Second Sight Medical Products Announces Closing of Public Offering
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable
About this update from Vivani Medical, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nSecond Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriter’s option to purchase additional shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were $57,500,000, before deducting underwriting discounts, commissions and other offering expenses.\n\nThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.\n\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\n\nThe securities were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 8, 2021 and declared effective on June 14, 2021. The offering was made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at [email protected].\n\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n\nAbout the Orion Visual Cortical Prosthesis System\n\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical...